A detailed history of American Century Companies Inc transactions in Erasca, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 284,206 shares of ERAS stock, worth $721,883. This represents 0.0% of its overall portfolio holdings.

Number of Shares
284,206
Previous 130,407 117.94%
Holding current value
$721,883
Previous $307,000 152.44%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.17 - $3.28 $333,743 - $504,460
153,799 Added 117.94%
284,206 $775,000
Q2 2024

Aug 07, 2024

BUY
$1.79 - $2.63 $85,771 - $126,021
47,917 Added 58.09%
130,407 $307,000
Q1 2024

May 14, 2024

BUY
$1.67 - $2.55 $37,000 - $56,497
22,156 Added 36.72%
82,490 $169,000
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.49 $100,757 - $150,231
60,334 New
60,334 $128,000
Q3 2023

Nov 13, 2023

BUY
$1.97 - $2.91 $22,268 - $32,894
11,304 Added 38.84%
40,410 $79,000
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $41,487 - $53,271
16,143 Added 124.53%
29,106 $80,000
Q1 2023

May 11, 2023

BUY
$2.74 - $4.44 $35,518 - $57,555
12,963 New
12,963 $39,000
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $17,477 - $32,072
3,003 Added 0.99%
306,540 $2.39 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $8.72 $1,662 - $3,165
363 Added 0.12%
303,537 $1.69 Million
Q1 2022

May 11, 2022

BUY
$8.6 - $15.48 $1,023 - $1,842
119 Added 0.04%
303,174 $2.61 Million
Q4 2021

Feb 07, 2022

BUY
$12.51 - $22.75 $124,086 - $225,657
9,919 Added 3.38%
303,055 $4.72 Million
Q3 2021

Nov 10, 2021

BUY
$17.43 - $24.34 $5.11 Million - $7.13 Million
293,136 New
293,136 $6.22 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $310M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.